Puretech Health PLC Company Profile (LON:PRTC)

About Puretech Health PLC (LON:PRTC)

Puretech Health PLC logoPureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:PRTC
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: £277.22 million
  • Outstanding Shares: 232,712,000
Average Prices:
  • 50 Day Moving Avg: GBX 115.98
  • 200 Day Moving Avg: GBX 120.37
  • 52 Week Range: GBX 110 - GBX 170
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £4.43 million
  • Price / Sales: 62.58
  • Book Value: GBX 0.76 per share
  • Price / Book: 1.56
Profitability:
  • EBIDTA: ($72,360,000.00)
Misc:
  • Average Volume: 82,110 shs.
 

Frequently Asked Questions for Puretech Health PLC (LON:PRTC)

What is Puretech Health PLC's stock symbol?

Puretech Health PLC trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

Where is Puretech Health PLC's stock going? Where will Puretech Health PLC's stock price be in 2017?

5 brokerages have issued 1-year target prices for Puretech Health PLC's shares. Their predictions range from GBX 246 to GBX 259. On average, they anticipate Puretech Health PLC's share price to reach GBX 252.80 in the next year. View Analyst Ratings for Puretech Health PLC.

Who are some of Puretech Health PLC's key competitors?

How do I buy Puretech Health PLC stock?

Shares of Puretech Health PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of Puretech Health PLC stock cost?

One share of Puretech Health PLC stock can currently be purchased for approximately GBX 119.13.

Analyst Ratings

Consensus Ratings for Puretech Health PLC (LON:PRTC) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 252.80

Analysts' Ratings History for Puretech Health PLC (LON:PRTC)
Show:
DateFirmActionRatingPrice TargetDetails
5/16/2017N+1 SingerReiterated RatingBuyGBX 256View Rating Details
5/10/2017Peel HuntReiterated RatingBuyGBX 259View Rating Details
5/10/2017Liberum CapitalReiterated RatingBuyGBX 248View Rating Details
4/6/2017Jefferies Group LLCReiterated RatingBuyGBX 255View Rating Details
4/4/2017Numis Securities LtdReiterated RatingBuyGBX 220 -> GBX 246View Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Puretech Health PLC (LON:PRTC)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Puretech Health PLC (LON:PRTC)
Current Year EPS Consensus Estimate: $-0.270 EPS

Dividends

Dividend History for Puretech Health PLC (LON:PRTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Puretech Health PLC (LON:PRTC)
Insider Trades by Quarter for Puretech Health PLC (LON:PRTC)
Insider Trades by Quarter for Puretech Health PLC (LON:PRTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/28/2016Scardino,Dame MarjorieInsiderBuy5,000GBX 135£6,750
10/26/2015Ito,JoichiInsiderBuy6,650GBX 149£9,908.50
10/9/2015Scardino,MarjorieInsiderBuy6,890GBX 126£8,681.40
9/28/2015Langer,RobertInsiderBuy7,200GBX 135£9,720
9/16/2015LaMattina,JohnInsiderBuy11,000GBX 146£16,060
9/10/2015LaMattina,JohnInsiderBuy5,492GBX 146£8,018.32
9/9/2015LaMattina,JohnInsiderBuy11,000GBX 147£16,170
9/4/2015LaMattina,JohnInsiderBuy11,000GBX 138£15,180
9/3/2015Scardino,MarjorieInsiderBuy10,000GBX 135£13,500
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Puretech Health PLC (LON:PRTC)
Latest Headlines for Puretech Health PLC (LON:PRTC)
Source:
DateHeadline
finance.yahoo.com logoKaruna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
finance.yahoo.com - May 19 at 12:08 PM
finance.yahoo.com logoSync Project Announces New Investors and Accelerates Development of Personalized Music Health Platform
finance.yahoo.com - May 17 at 8:26 AM
finance.yahoo.com logoVedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia
finance.yahoo.com - May 16 at 9:45 AM
businesswire.com logoPureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of ... - Business Wire (press release)
www.businesswire.com - May 11 at 8:30 AM
finance.yahoo.com logoPureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections
finance.yahoo.com - May 9 at 11:00 AM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bearish Manner : PRTC-GB : May 5, 2017
finance.yahoo.com - May 5 at 8:29 AM
finance.yahoo.com logoPureTech Health Announces Licensing Agreement between Commense and the University of British Columbia for Microbiome-Derived Therapy
finance.yahoo.com - May 5 at 8:29 AM
finance.yahoo.com logoGelesis Announces €2.9 Million Award from Italian Ministry of Economic Development
finance.yahoo.com - May 3 at 7:40 PM
finance.yahoo.com logoPureTech Health Plc :PRTC-GB: Earnings Analysis: For the six months ended December 31, 2016 : April 26, 2017
finance.yahoo.com - April 26 at 10:59 PM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bearish Manner : PRTC-GB : April 24, 2017
finance.yahoo.com - April 24 at 2:31 PM
finance.yahoo.com logo[$$] Gormley's Take: With Risks, Medical Startup Investments Come to Masses
finance.yahoo.com - April 21 at 8:50 AM
finance.yahoo.com logoresTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer - Yahoo Finance
finance.yahoo.com - April 14 at 6:54 PM
finance.yahoo.com logoresTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer
finance.yahoo.com - April 13 at 9:39 AM
finance.yahoo.com logoPureTech Health Plc – Value Analysis (LONDON:PRTC) : April 12, 2017
finance.yahoo.com - April 12 at 1:44 PM
finance.yahoo.com logoPureTech Health Advances New Program Targeting Immunosuppressive Gamma Delta T Cells and Related Mechanisms
finance.yahoo.com - April 11 at 10:19 AM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bullish Manner : PRTC-GB : April 11, 2017
finance.yahoo.com - April 11 at 10:19 AM
americanbankingnews.com logoLiberum Capital Reiterates "Buy" Rating for Puretech Health PLC (PRTC)
www.americanbankingnews.com - April 8 at 10:56 AM
finance.yahoo.com logoAkili Announces Results from Pilot Study Showing Treatment with Project EVO™ Improves Cognitive Control in Children with Sensory Processing Dysfunction and Attentional Deficits
finance.yahoo.com - April 7 at 12:02 PM
americanbankingnews.com logoJefferies Group LLC Reiterates "Buy" Rating for Puretech Health PLC (PRTC)
www.americanbankingnews.com - April 6 at 8:28 PM
americanbankingnews.com logoPuretech Health PLC (PRTC) Stock Rating Reaffirmed by N+1 Singer
www.americanbankingnews.com - April 6 at 1:43 PM
americanbankingnews.com logoPuretech Health PLC (PRTC) Price Target Raised to GBX 246
www.americanbankingnews.com - April 4 at 1:18 PM
americanbankingnews.com logoPuretech Health PLC (PRTC) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 4 at 1:16 AM
americanbankingnews.com logoPuretech Health PLC's (PRTC) "Buy" Rating Reiterated at Numis Securities Ltd
www.americanbankingnews.com - March 30 at 5:43 AM
businesswire.com logoPureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 ... - Business Wire (press release)
www.businesswire.com - March 25 at 6:56 PM
americanbankingnews.com logoPuretech Health PLC (PRTC) Stock Rating Reaffirmed by Numis Securities Ltd
www.americanbankingnews.com - March 24 at 1:07 PM
finance.yahoo.com logoPureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 Programs
finance.yahoo.com - March 24 at 8:16 AM
americanbankingnews.com logoPuretech Health PLC's (PRTC) Buy Rating Reiterated at Peel Hunt
www.americanbankingnews.com - March 24 at 6:07 AM
uk.finance.yahoo.com logoPureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy
uk.finance.yahoo.com - March 2 at 8:30 AM
businesswire.com logoPureTech Health to Present at the Cowen and Company 37th Annual Health Care Conference - Business Wire (press release)
www.businesswire.com - February 25 at 1:39 AM
finance.yahoo.com logoPureTech Health to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 24 at 8:21 AM
uk.finance.yahoo.com logoPureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer
uk.finance.yahoo.com - February 23 at 8:49 AM
finance.yahoo.com logoVedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University …
finance.yahoo.com - February 17 at 8:06 PM
uk.finance.yahoo.com logoPureTech Health to Present at the Leerink Partners 6th Annual Global Healthcare Conference
uk.finance.yahoo.com - February 7 at 8:47 AM
finance.yahoo.com logoKaruna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimer's
finance.yahoo.com - December 15 at 9:07 PM
finance.yahoo.com logoAdministration of Gelesis200 Increases Fullness and Satiety in People who are Overweight or Have Obesity
finance.yahoo.com - November 4 at 10:40 AM
uk.finance.yahoo.com logoPureTech Health to Present at the Jefferies 2016 Healthcare Conference in London
uk.finance.yahoo.com - November 2 at 10:30 AM
finance.yahoo.com logoPureTech Appoints Industry Leader Joseph Bolen as Chief Scientific Officer
finance.yahoo.com - October 20 at 8:16 AM
uk.finance.yahoo.com logoVedanta Biosciences Granted First European Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia
uk.finance.yahoo.com - October 19 at 3:26 PM
finance.yahoo.com logoKaruna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate
finance.yahoo.com - September 12 at 11:31 AM
biz.yahoo.com logoHalf Year 2016 PureTech Health PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 7 at 10:25 AM
finance.yahoo.com logoVedanta Biosciences Granted Third U.S. Patent Covering Methods of Treating Infectious and Allergic Diseases with Bacterial Consortia
finance.yahoo.com - September 6 at 11:39 AM
finance.yahoo.com logoGelesis Appoints New Chief Operating Officer
finance.yahoo.com - September 2 at 11:46 AM
finance.yahoo.com logoVedanta Biosciences Granted Second U.S. Patent Covering Methods of Treating Autoimmune Disease with Therapeutics Based on Bacterial Consortia
finance.yahoo.com - August 23 at 11:27 AM
uk.finance.yahoo.com logoVedanta Biosciences Granted U.S. Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia
uk.finance.yahoo.com - August 16 at 10:10 AM

Social

Puretech Health PLC (PRTC) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff